AI-enabled blood analyser for home health monitoring revealed at historic venue in London

Algocyte^® has unveiled Algocyte PROXIMA™, an AI-enabled Mobile Health Station (MHS) for home and community blood testing, at the Royal Society of Medicine (RSM) in London. The launch brought together NHS clinicians, university researchers and healthcare innovators to see how this UK-designed and UK-manufactured complete blood count (FBC) analyser aims to support preventative and personalized healthcare by enabling regular, remote blood monitoring outside traditional hospital laboratories.

First UK-designed and UK-manufactured FBC analyzer

Algocyte PROXIMA is a hematology medical instrument and the first UK-designed and UK-manufactured complete blood count analyzer. While several other countries have developed FBC analyzers, Algocyte PROXIMA represents the UK’s first entry in this class of diagnostic instrument, offering the full range of parameters that constitute an FBC test, one of the most widely used and clinically relevant medical diagnostics worldwide.

Patient-centric, ultra-portable blood testing

Unlike other analyzers in the global market, Algocyte PROXIMA is designed to be patient-centric and ultra-portable. It is intended for use by non-specialized healthcare providers rather than laboratory technicians or phlebotomists, enabling regular blood monitoring in homes, community hubs and other non-hospital settings. The device requires only a small blood sample comparable to that used by a glucose meter, supporting more frequent testing with minimal burden on patients.

Expert perspectives from leading clinicians and researchers

The launch event at the Royal Society of Medicine featured insights from internationally recognized experts working across healthcare engineering, transplantation, bioscience and artificial intelligence. Speakers included Dr. Hector Zenil FRSM from King’s College London, Prof. Kourosh Saeb-Parsy FRCS from the University of Cambridge, Prof. Jesper Tegnér from KAUST and Dr. Narsis Kiani from the Karolinska Institute.

Dr. Zenil, Founder and CEO of Algocyte, commented: “Healthcare has traditionally relied on seldom measurements taken during periods of illness. Our ambition is to move towards a better understanding of the transition between health and disease by taking more regular measurements.”

He added: “We believe the medical instruments of the 21st century should be as connected, portable, and intuitive as the smartphones and devices we use at home.”

From snapshot blood tests to continuous health monitoring

Traditional blood testing typically provides a snapshot of health at a single point in time, often when someone is already unwell. Algocyte PROXIMA is designed to track biological markers over time, supporting a shift from reactive to preventative care.

In a future release, Algocyte plans for Algocyte PROXIMA to combine longitudinal biological data with lifestyle information, symptoms and other health records to build a more complete picture of an individual’s health status.

Using artificial intelligence to analyze personal trends alongside millions of aggregated blood test trends and biomarker profiles, the Algocyte Health Hub will help establish a personal health baseline and identify changes over time.

“By combining advanced blood analysis, AI and individual health data, we want to support earlier insight and more personalized healthcare decisions, for better outcomes,” said Dr. Zenil.

Physics-informed hybrid AI architecture

Algocyte PROXIMA performs blood analysis using a hybrid, physics-informed AI architecture that combines two independent sensing modalities: bright field imaging and spectrometry. These sensing modalities keep the AI models grounded in physical measurements.

“By grounding outputs in measurable physical parameters and cross-validating signals between sensors, this design constrains model behaviour and supports better performance,” added Dr. Zenil.

Immersive virtual reality training with Apple Vision Pro

The event also showcased Algocyte’s immersive virtual reality training platform, built using Apple Vision Pro, a first for a medical instrument of this type. The VR platform enables healthcare professionals and patients to learn how to operate Algocyte PROXIMA within a fully virtual environment that simulates the complete blood testing workflow, from sample collection to result interpretation.

Regulatory milestones and international pilot programmes

At the Royal Society of Medicine event, Algocyte announced that Algocyte PROXIMA has achieved the UKCA mark as a UK IVD general class medical instrument, marking readiness for commercial deployment in the UK.

The company also outlined its next phase of international expansion, which will focus on progressing regulatory pathways in additional jurisdictions. This work will be supported by early-stage pilot programmes in the UK, Canada and the UAE. These pilots include initial positive feedback from NHS laboratory operators and a Canadian government rural community hub where the device is currently under evaluation.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>